FINWIRES · TerminalLIVE
FINWIRES

BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study

By

BriaCell Therapeutics (BCT.TO) said on Wednesday that the US Food and Drug Administration cleared the way for the company to initiate a Phase 1/2a clinical study of its prostate cancer immunotherapy candidate Bria-PROS+.

The agency issued a "Study May Proceed" letter after reviewing BriaCell's Investigational New Drug application for Bria-PROS+, a statement said.

BriaCell was awarded a $2 million grant from the US National Cancer Institute last year to support the manufacturing and clinical evaluation of Bria-PROS+.

BrlaCell shares were last seen up C$0.22 at C$4.93 on the Toronto Stock Exchange.

Price: $4.90, Change: $+0.19, Percent Change: +4.03%

Related Articles

Mining & Metals

PHX Energy Q2 Earnings Beat Estimates as Revenue Rises 7%

PHX Energy Services (PHX.TO) reported second-quarter earnings of C$0.21 per share, or C$10.97 million, compared with C$0.17 per share, or C$8.52 million, in the prior-year period. The results topped FactSet analysts' estimate of C$0.18 per share.For the three months ended June 30, 2026, revenue rose 7% to C$178.9 million from C$167.7 million in the second quarter of 2025.In its outlook, PHX said North American industry activity is showing an uptick in the third quarter, supported by strengthening commodity prices.Company's shares closed up C$0.28 to C$10.92 on Toronto stock Exchange on Tuesday.

$PHX.TO
Mining & Metals

Earnings Flash (PHX.TO) PHX Energy Services Corp. Reports Q2 Revenue C$178.9M

$PHX.TO
Mining & Metals

Earnings Flash (SU.TO) Suncor Energy Inc. Posts Q2 Adjusted EPS C$3.23 per Share, vs. FactSet Est of C$3.04

$SU.TO